DNL343 for ALS
What You Need to Know Before You Apply
What is the purpose of this trial?
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.Regimen G will evaluate the safety and efficacy of a single study drug, DNL343, in participants with ALS.
Who Is on the Research Team?
Merit Cudkowicz, MD
Principal Investigator
Massachusetts General Hospital
Are You a Good Fit for This Trial?
This trial is for people with ALS, also known as Lou Gehrig's disease. Participants must not have had a seizure in the last 6 months and cannot be taking certain medications that affect liver enzymes or drug transporters.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants complete a baseline assessment before randomization
Treatment
Participants receive either active DNL343 or matching placebo
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- DNL343
- Matching Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Merit E. Cudkowicz, MD
Lead Sponsor
Denali Therapeutics Inc.
Industry Sponsor